K08670766

Kromasil^® C8 HPLC Column

5 μm particle size, pore size 100 Å, L × I.D. 150 mm × 4.6 mm

• UNSPSC Code: 41115700
• eCl@ss: 32110501
• NACRES: NB.21

Properties

• product line: Kromasil^®
• manufacturer/tradename: Kromasil^® KR100-5-C8-4.6X150
• availability: available only in USA, Canada and Puerto Rico; available only in USA, Canada and Puerto Rico
• technique(s): HPLC: suitable
• L × I.D.: 150 mm × 4.6 mm
• matrix active group: C8 (octyl) phase
• particle size: 5 μm
• pore size: 100 Å
• application(s): food and beverages
• separation technique: reversed phase

Description

Application

• Analytical Method Development, Validation and Forced Degradation Study of Dapagliflozin by RP-HPLC: Utilizing the Kromasil^® C8 HPLC column, this study demonstrated the column′s robustness in pharmaceutical applications, particularly for the detailed analysis of Dapagliflozin, a diabetes medication. The research highlights the column′s effectiveness in handling complex degradation studies essential for drug stability testing (Chaudhari et al., 2023).


• Determination of Olmesartan in Bulk and Pharmaceutical Dosage Forms: This research outlines the use of the Kromasil^® C8 column for high-throughput quantification of Olmesartan, showcasing the column′s precision and repeatability in both bulk and dosage form analyses. The method is vital for quality control in pharmaceutical manufacturing (Agrawal et al., 2023).


• Quality control of substance benchmarks for Danggui Sini Decoction: The Kromasil^® C8 column was key in the standardized quality control of traditional Chinese medicine, proving its versatility and efficiency in herbal compound separation and analysis (Lu et al., 2022).


• HPLC fingerprint of Tibetan medicinal plant "Bangga" and chemical components analysis: This study employed the Kromasil^® C8 column to achieve detailed profiling and chemical analysis of Tibetan medicinal plants, further underscoring the column′s role in enhancing research in ethnopharmacology (Lu et al., 2021).


• Quantification of a New Antifungal Drug Based on 1,3,4-Thiadiazole by HPLC-ESI/MS: Highlighting the Kromasil^® C8 column′s high resolution and sensitivity, this study focuses on the development and validation of a method for quantifying a novel antifungal compound, essential for both pharmaceutical development and therapeutic monitoring (Sipkina et al., 2022).

Legal Information

Kromasil is a registered trademark of EKA Chemicals AB